Anti-LAG-3 antibody LBL-007 plus anti-PD-1 antibody toripalimab in advanced nasopharyngeal carcinoma and other solid tumors: an open-label, multicenter, phase Ib/II trial
LBL-007 plus toripalimab exhibited a manageable safety profile in patients with advanced solid tumors and demonstrated promising antitumor activity in NPC, especially in immunotherapy-naive patients. These findings warrant further validation in future studies.
Authors
- Xiaoqiang Kang (ORCID: https://orcid.org/0000-0001-6685-2343)
- Jinguan Lin
- Suxia Luo (ORCID: https://orcid.org/0000-0002-5267-8417)
- Yuanyuan Zhao (ORCID: https://orcid.org/0000-0002-7148-7608)
- Dong-Chen Sun
- Yunpeng Yang (ORCID: https://orcid.org/0000-0001-5163-0940)
- Yi Ba
- W. Wang (ORCID: https://orcid.org/0000-0001-9354-6931)
- Ting Zhou (ORCID: https://orcid.org/0000-0003-4349-2036)
- Li Zhang (ORCID: https://orcid.org/0000-0002-9507-7320)
- Gang Chen (ORCID: https://orcid.org/0000-0002-2378-6056)
- Zhen Wang (ORCID: https://orcid.org/0000-0001-9289-4889)
- Huili Wang (ORCID: https://orcid.org/0000-0002-0984-2963)
- Guiling Li (ORCID: https://orcid.org/0000-0002-3220-7554)
- Yan Huang (ORCID: https://orcid.org/0000-0002-2072-0190)
- Hong-Yun Zhao
- Desheng Hu (ORCID: https://orcid.org/0000-0001-9298-5545)
- Wenfeng Fang (ORCID: https://orcid.org/0000-0002-6440-8246)
- Chao Deng (ORCID: https://orcid.org/0000-0003-1661-2450)
- Zhichao Fu (ORCID: https://orcid.org/0000-0003-0341-106X)
- Haisheng Zhu
- Ya-Xiong Zhang
- Shengli Cai (ORCID: https://orcid.org/0009-0008-6542-5962)
Institutions
- Union Hospital (HK)
- Sun Yat-sen University (CN)
- Tianjin Medical University Cancer Institute and Hospital (CN)
- Hunan Cancer Hospital (CN)
- New England Biolabs (China) (CN)
- Henan Cancer Hospital (CN)
- Sun Yat-sen University Cancer Center (CN)
- Hubei Cancer Hospital (CN)
- Yulin University (CN)
- Affiliated Hospital of Jining Medical University (CN)
- Huazhong University of Science and Technology (CN)
Publication Details
- Journal
- Journal of Hematology & Oncology
- Published
- 2025-02-07
- DOI
- https://doi.org/10.1186/s13045-025-01666-6
- Citations
- 20
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 20.91
Funders
- National Natural Science Foundation of China
- China Postdoctoral Science Foundation